Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.61 |
| ▸ | CA1 | P00915 | 3/20 | 0.61 |
| ▸ | CA2 | P00918 | 3/20 | 0.61 |
| ▸ | CA9 | Q16790 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL165673 | 0.98 | CA12 (0.60) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL21065340 | 0.89 | CA12 (0.48) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL9990508 | 0.88 | SMN1; SMN2 (0.57) | CA12CA1CA2CA9ALDH1A1 | |
| Cyclohexanol SCHEMBL9499967 | 0.88 | CA12 (0.50) | CA12CA1CA2CA9ALDH1A1 | |
| Cyclohexanol SCHEMBL9497715 | 0.88 | CA12 (0.50) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL7068538 | 0.86 | RAD52 (0.55) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL9990414 | 0.85 | SMN1; SMN2 (0.53) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL3893911 | 0.84 | CA12 (0.63) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL2755862 | 0.83 | RAD52 (0.53) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL18824247 | 0.83 | HDAC2 (0.49) | CA12CA1CA2CA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8614211-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC. (US) | 2013-12-24 | — | — | US | claimed |
| US-20130040945-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2013-02-14 | — | — | US | claimed |
| WO-2013023145-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. (US) | 2013-02-14 | — | — | WO | claimed |
| WO-2024019936-A1 | NANOMATERIALS COMPRISING TRIOLS | BEAM THERAPEUTICS INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| US-20230331737-A1 | MTORC1 MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230151052-A1 | NEUROSTEROID COMPOUNDS AND METHODS FOR THEIR PREPARATION AND USE IN TREATING CENTRAL NERVOUS SYSTEM DISORDERS | THE TEXAS A&M UNIVERSITY SYSTEM | 2023-05-18 | — | — | US | disclosed |
| US-11542296-B2 | Neurosteroid compounds and methods for their preparation and use in treating central nervous system disorders | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2023-01-03 | — | — | US | disclosed |
| EP-3950692-A1 | NOVEL TRICYCLIC COMPOUNDS | AbbVie Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| US-20210238220-A1 | NEUROSTEROID COMPOUNDS AND METHODS FOR THEIR PREPARATION AND USE IN TREATING CENTRAL NERVOUS SYSTEM DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-08-05 | — | — | US | disclosed |
| CN-109053742-B | Novel tricyclic compounds | ABBVIE 公司 | 2021-06-15 | — | — | CN | disclosed |
| US-20210061813-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2021-03-04 | — | — | US | disclosed |
| CN-102498095-A | Indoline derivatives | TOKYO INST TECH | 2012-06-13 | — | — | CN | disclosed |
| US-20110311474-A1 | Novel Tricyclic Compounds | ABBOTT LABORATORIES (US) | 2011-12-22 | — | — | US | disclosed |
| WO-2011068881-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-09 | — | — | WO | disclosed |
| US-7671072-B2 | Aminopyrazole derivatives as GSK-3 inhibitors | PFIZER INC. (US) | 2010-03-02 | — | — | US | disclosed |
| WO-2009033165-A1 | HYPOXIA ACTIVATED PRODRUGS OF BIS-ALKYLATING AGENTS | THRESHOLD PHARMACEUTICALS, INC. (US) | 2009-03-12 | — | — | WO | disclosed |
| US-20070276010-A1 | Aminopyrazole Derivatives as Gsk-3 Inhibitors | BENBOW JOHN W | 2007-11-29 | — | — | US | disclosed |
| US-6740741-B2 | SUCH AS (2-(1-PIPERIDINE)ETHYL)CARBAMATE FOR THE DEACIDIFICATION OF PAPER MATERIAL | CONSIGLIO NAZIONALE DELLE RICERCHE (IT) | 2004-05-25 | — | — | US | disclosed |
| US-20030065153-A1 | Novel diazo derivatives and process for their preparation | ZAPPALA ANTONIO (IT) | 2003-04-03 | — | — | US | disclosed |
| EP-1273568-A2 | Novel diazo derivatives and process for their preparation | CONSIGLIO NAZIONALE DELLE RICERCHE (IT) | 2003-01-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151052-A1 | NEUROSTEROID COMPOUNDS AND METHODS FOR THEIR PREPARATION AND USE IN TREATING CENTRAL NERVOUS SYSTEM DISORDERS | CYP11B2, CYP21A2, CYP11B1 | CA12 2607/4885CA1 1841/4885CA2 3374/4885 |
| US-20070276010-A1 | Aminopyrazole Derivatives as Gsk-3 Inhibitors | GSK3B, GSK3A, GSKIP | CA12 3894/4885CA1 2361/4885CA2 3175/4885 |
| US-20210238220-A1 | NEUROSTEROID COMPOUNDS AND METHODS FOR THEIR PREPARATION AND USE IN TREATING CENTRAL NERVOUS SYSTEM DISORDERS | CYP11B2, CYP21A2, CYP11B1 | CA12 2607/4885CA1 1841/4885CA2 3374/4885 |
| US-20030065153-A1 | Novel diazo derivatives and process for their preparation | DDT, DDC, ACMSD | CA12 1321/4885CA1 1594/4885CA2 2144/4885 |
| US-20230331737-A1 | MTORC1 MODULATORS AND USES THEREOF | MTOR, RPTOR, RICTOR | CA12 4798/4885CA1 4771/4885CA2 4043/4885 |
| US-20210061813-A1 | NOVEL TRICYCLIC COMPOUNDS | CYP11B2, CYP11B1, ABCB1 | CA12 641/4885CA1 1857/4885CA2 1833/4885 |
| US-11542296-B2 | Neurosteroid compounds and methods for their preparation and use in treating central nervous system disorders | CYP11B2, CYP21A2, CYP11B1 | CA12 2607/4885CA1 1841/4885CA2 3374/4885 |
| US-20110311474-A1 | Novel Tricyclic Compounds | CYP11B2, CYP11B1, ABCB1 | CA12 641/4885CA1 1857/4885CA2 1833/4885 |
| US-20130040945-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | RXRG, ARNT, RARS2 | CA12 986/4885CA1 2686/4885CA2 2121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.